ArchPoint Investors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

ArchPoint Investors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.73M	Hold	29,875	–	–	1%	21
2026 Q1	$3.82M	Hold	29,875	–	–	0.91%	25
2025 Q4	$3.64M	Hold	29,875	–	–	0.86%	22
2025 Q3	$2.99M	Hold	29,875	–	–	0.82%	31
2025 Q2	$2.48M	Hold	29,875	–	–	0.73%	34
2025 Q1	$2.42M	Buy	29,875 +875	+3%	+$78.2K	0.8%	30
2024 Q4	$2.61M	Sell	29,000 -875	-3%	-$84.8K	0.86%	28
2024 Q3	$2.95M	Sell	29,875 -14,618	-33%	-$1.44M	0.99%	23
2024 Q2	$4.12M	Hold	44,493	–	–	1.55%	18
2024 Q1	$4.22M	Buy	+44,493	New	+$4.13M	1.76%	18
2021 Q2	–	Sell	-7,000	Closed	-$950K	–	115
2021 Q1	$950K	Hold	7,000	–	–	0.27%	58
2020 Q4	$985K	Hold	7,000	–	–	0.27%	56
2020 Q3	$780K	Hold	7,000	–	–	0.25%	52
2020 Q2	$784K	Hold	7,000	–	–	0.25%	38
2020 Q1	$542K	Hold	7,000	–	–	0.21%	51
2019 Q4	$666K	Hold	7,000	–	–	0.2%	54
2019 Q3	$534K	Hold	7,000	–	–	0.18%	54
2019 Q2	$614K	Hold	7,000	–	–	0.19%	49
2019 Q1	$634K	Sell	7,000 -48,896	-87%	-$4.16M	0.19%	49
2018 Q4	$4.01M	Sell	55,896 -38,228	-41%	-$3.08M	1.39%	15
2018 Q3	$9.02M	Buy	94,124 +1,247	+1%	+$121K	2.45%	7
2018 Q2	$8.84M	Buy	92,877 +2,660	+3%	+$244K	2.55%	8
2018 Q1	$7.92M	Sell	90,217 -840	-0.9%	-$76.7K	2.33%	7
2017 Q4	$7.73M	Buy	91,057 +8,150	+10%	+$683K	2.41%	8
2017 Q3	$7.18M	Buy	82,907 +950	+1%	+$76.2K	2.29%	8
2017 Q2	$6.33M	Buy	81,957 +44,231	+117%	+$3.14M	2.01%	8
2017 Q1	$2.62M	Sell	37,726 -274	-0.7%	-$18.4K	0.98%	23
2016 Q4	$2.25M	Buy	+38,000	New	+$2.35M	1.32%	22

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

ArchPoint Investors's XBI Position: Q2 2026 in Review

ArchPoint Investors held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 29,875 shares worth $4.73M. The position accounts for 1% of the portfolio, ranked #21.

ArchPoint Investors first reported a position in XBI in Q4 2016 and has held it in 28 quarters since. The position peaked at $9.02M in Q3 2018. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

ArchPoint Investors held 29,875 shares of State Street SPDR S&P Biotech ETF worth $4.73M as of Q2 2026.
ArchPoint Investors left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
State Street SPDR S&P Biotech ETF made up 1% of ArchPoint Investors's portfolio in Q2 2026, its #21 holding.
ArchPoint Investors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and has held it in 28 quarters since.
ArchPoint Investors's State Street SPDR S&P Biotech ETF position peaked at $9.02M in Q3 2018.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on ArchPoint Investors's 13F filing for Q2 2026, filed 13 Aug 2026.